Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable … (Business Wire via Yahoo! Finance)

Posted on November 30, 2009 by admin

More info…
CAMBRIDGE, Mass.—-Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension for the treatment of opioid dependence.

naltrexone drug

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google Bookmarks
  • Yahoo! Buzz
  • TwitThis
  • Live
  • LinkedIn
  • Pownce
  • MySpace
This entry was posted in Naltrexone For Addiction. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Security Code: